The objective of the clinical study is to assess the efficacy of EMI-137 in aiding clinicians to detect pathological lesions during colonoscopy. The study will involve up to 200 patients with a high suspicion of CRC. Interim results from the trial are expected in Q1 2018. EM Imaging and CHDR collaborated on the Phase I study of EMI-137 which showed a 25% increase in bowel cancer lesion detection compared to standard colonoscopy.
Improved polyp detection in this study might lead to further studies in extended target populations and, possibly, in the end to a wider adoption of fluorescence-guided endoscopy.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
EM Imaging is also working with doctors and clinical centres in the UK, Europe, US and Asia to use EMI-137 to detect tumours during surgery. Studies are planned to look at improving cancer detection in a range of cancers including Breast Cancer, Gastric Cancer, Thyroid Cancer, Head & Neck Cancer, Prostate Cancer and Brain Cancer.
About Edinburgh Molecular Imaging
Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image-guided therapy. The Company's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.
EM Imaging discovers and develops small molecules and peptides that, when conjugated with fluorescent dyes, targets diseased tissue - specifically cancerous cells. This will provide the clinician with a clearer view and decision-making tool to benefit the patient. For more information go to: www.edinimage.com
About Centre for Human Drug Research
The Centre for Human Drug Research (CHDR) is a world renown Clinical Research Organisation in Leiden, The Netherlands with strong academic links which focuses on early drug development. Its mission is to develop compounds, therapeutic or diagnostic in an innovative and highly informative manner to allow early introduction of novel treatment paradigms into the clinic. www.chdr.nl
About Epidarex Capital
Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets in the US and Europe. With offices in Bethesda, Maryland and in Edinburgh, Scotland, Epidarex works closely with the management of its portfolio companies to more effectively translate their world-class research to commercial, patient-driven success.
